HYPOTHESIS 1. Neurocognitive deficits in cancer survivors are underestimated. They represent a very limiting long-term side effect in this group of patients. 2. An individualized, planned and limited intervention using technological gaming can improve neurocognitive function in these pediatric patients by taking advantage of the plasticity of the central nervous system (CNS) in the pediatric age. 3. Changes can be demonstrated not only at the cognitive level, but also at the structural and functional level using neuroimaging techniques after our intervention. 4. In addition to the aforementioned benefits, this therapeutic tool can improve some clinical-analytical markers used in the follow-up of cancer survivors, such as immunological markers like lymphocyte populations and inflammatory cytokines. 5. The neurocognitive effects of this therapy are not only produced at the time of the intervention, but remain until months after the intervention. 6. The positive impact of the treatment is not only observed in the patients, but also in the psychological and emotional state of the family members. VARIABLES 1. Clinically relevant improvement with moderate or large effect size in the following parameters as measured by neuropsychological tests. 2. Statistically significant changes in neuroimaging tests. 3. Statistically significant changes in immune and inflammatory biomarkers before and after treatment. STUDY DESIGN In this clinical trial, randomized versus control group, unblinded, the aim is to demonstrate the neuropsychological, structural and functional benefit of an intervention using video games in child cancer survivors. POPULATION OF THE STUDY The target population participating in the study will include patients of either sex aged 8-17 years who completed cancer treatment 1-5 years ago. They must have received treatment with neurotoxic potential: intrathecal/intraventricular chemotherapy, high-dose chemotherapy with crossing of the blood-brain barrier, CNS radiotherapy or hematopoietic stem cell transplantation (HSCT).
BACKGROUND AND RATIONALE Several authors have described specific cognitive damage following cancer treatments (often chemotherapy and radiotherapy), which has been termed "chemo-brain". This condition produces alterations in different neurocognitive fields such as memory, learning, concentration, reasoning, executive functions, attention and visuospatial skills. In this research project the investigator team propose an intervention aimed at one of the most limiting adverse effects of cancer and its treatment such as neurocognitive deficits through technological game platforms and brain training used in a directed, controlled and supervised manner. HYPOTHESIS 1. Neurocognitive deficits in cancer survivors are underestimated. They represent a very limiting long-term side effect in this group of patients. 2. An individualized, planned and limited intervention using technological gaming can improve neurocognitive function in these pediatric patients by taking advantage of the plasticity of the central nervous system (CNS) in the pediatric age. 3. Changes can be demonstrated not only at the cognitive level, but also at the structural and functional level using neuroimaging techniques after our intervention. 4. In addition to the aforementioned benefits, this therapeutic tool can improve some clinical-analytical markers used in the follow-up of cancer survivors, such as immunological markers like lymphocyte populations and inflammatory cytokines. 5. The neurocognitive effects of this therapy are not only produced at the time of the intervention, but remain until months after the intervention. 6. The positive impact of the treatment is not only observed in the patients, but also in the psychological and emotional state of the family members. VARIABLES 1. Clinically relevant improvement with moderate or large effect size in the following parameters as measured by neuropsychological tests: TAVECI/TAVEC, CATA, TONI-4 (form A), Digits, SDMT, ROCF, TFV, Stroop, Vocabulary 2. Statistically significant changes in neuroimaging tests. The following variables will be measured: 1. Structural imaging: volume measurement and Voxel Based Morphometry 2. Diffusion Imaging: diffusion maps and structural connectivity 3. Functional imaging: resting state and task based fMRI 3. Statistically significant changes in immune and inflammatory biomarkers before and after treatment: 1. Study of lymphocyte populations by parametric flow cytometry: T lymphocytes, B lymphocytes, natural killer (NK) lymphocytes, NK T lymphocytes 2. Study of inflammatory cytokines by LUMINEX: IL-2, IL-4, IL-6, TNF alpha, IFN gamma, IL-10, IL-17TH, IL-1R antagonist STUDY DESIGN In this clinical trial, randomized versus control group, unblinded, the aim is to demonstrate the neuropsychological, structural and functional benefit of an intervention using video games in child cancer survivors, patients will follow the following phases: * Informed consent * Recruitment, inclusion and exclusion criteria. * Initial T0 assessment * Randomization * Treatment phase for the intervention group. Waiting phase for control group * Early post-treatment evaluation T+3 * Late post-treatment evaluation T+6 POPULATION OF THE STUDY The target population participating in the study will include patients of either sex aged 8-17 years who completed cancer treatment 1-5 years ago. They must have received treatment with neurotoxic potential: intrathecal/intraventricular chemotherapy, high-dose chemotherapy with crossing of the blood-brain barrier, CNS radiotherapy or hematopoietic stem cell transplantation (HSCT). TREATMENT OF THE STUDY Type of intervention Cognitive training through 3 types of video games: * "Serious games" or "brain-training games". * Exer-gaming * Skill-training games Method of administration The patient will receive the treatment for a period of 12 weeks, in which they will commit to use the video games of the intervention with the following pattern: * "Brain-training game": sessions of 7-12 minutes with a frequency of 4 days a week. * "Exer-gaming": sessions of 15-20 minutes 2 days a week. * "Skill-training games": sessions of 15-20 minutes 2 days a week. SAMPLE SIZE It is planned to recruit 56 patients (28 patients for each group, of which 14 will be from the 8-12 years age group and 14 will be from the 13-17 years age group). Recruitment will be for 12 months, with a follow-up period for each patient of 6 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
56
Type of intervention: Cognitive training through 3 types of video games: * "Serious games" or "brain-training games". * Exer-gaming * Skill-training games Method of administration: The patient will receive the treatment for a period of 12 weeks, in which they will commit to use the video games of the intervention with the following pattern: * "Brain-training game": sessions of 7-12 minutes with a frequency of 4 days a week. * "Exer-gaming": sessions of 15-20 minutes 2 days a week. * "Skill-training games": sessions of 15-20 minutes 2 days a week.
Hospital La Paz
Madrid, Spain
RECRUITINGSDMT Test
To evaluate the benefits of treatment at the neurocognitive level by means of neuropsychological tests.
Time frame: Baseline
Change in SDMT Test
To evaluate the benefits of treatment at the neurocognitive level by means of neuropsychological tests.
Time frame: At 3 months after recruitment
Change in SDMT Test
To evaluate the benefits of treatment at the neurocognitive level by means of neuropsychological tests.
Time frame: At 6 months after recruitment
"DIGITOS" Test
To evaluate the benefits of treatment at the neurocognitive level (processing speed)
Time frame: Baseline
Change in "DIGITOS" Test
To evaluate the benefits of treatment at the neurocognitive level (processing speed)
Time frame: At 3 months after recruitment
Change in "DIGITOS" Test
To evaluate the benefits of treatment at the neurocognitive level (processing speed)
Time frame: At 6 months after recruitment
"TONI-4" test
To evaluate the benefits of treatment at the neurocognitive level (non-verbal intelligence)
Time frame: Baseline
Change in "TONI-4" test
To evaluate the benefits of treatment at the neurocognitive level (non-verbal intelligence)
Time frame: At 3 months after recruitment
Change in "TONI-4" test
To evaluate the benefits of treatment at the neurocognitive level (non-verbal intelligence)
Time frame: At 6 months after recruitment
"ROCF" test
To evaluate the benefits of treatment at the neurocognitive level (visuo-constructional ability and non-verbal memory)
Time frame: Baseline
Change in "ROCF" test
To evaluate the benefits of treatment at the neurocognitive level (visuo-constructional ability and non-verbal memory)
Time frame: At 3 months after recruitment
Change in "ROCF" test
To evaluate the benefits of treatment at the neurocognitive level (visuo-constructional ability and non-verbal memory)
Time frame: At 6 months after recruitment
"TFV" test
To evaluate the benefits of treatment at the neurocognitive level (verbal fluency)
Time frame: Baseline
Change in "TFV" test
To evaluate the benefits of treatment at the neurocognitive level (verbal fluency)
Time frame: At 3 months after recruitment
Change in "TFV" test
To evaluate the benefits of treatment at the neurocognitive level (verbal fluency)
Time frame: At 6 months after recruitment
"STROOP" test
To evaluate the benefits of treatment at the neurocognitive level (selective attention and inhibitory control)
Time frame: Baseline
Change in "STROOP" test
To evaluate the benefits of treatment at the neurocognitive level (selective attention and inhibitory control)
Time frame: At 3 months after recruitment
Change in "STROOP" test
To evaluate the benefits of treatment at the neurocognitive level (selective attention and inhibitory control)
Time frame: At 6 months after recruitment
"TAVECI" test
To evaluate the benefits of treatment at the neurocognitive level (verbal learning)
Time frame: Baseline
Change in "TAVECI" test
To evaluate the benefits of treatment at the neurocognitive level (verbal learning)
Time frame: At 3 months after recruitment
Change in "TAVECI" test
To evaluate the benefits of treatment at the neurocognitive level (verbal learning)
Time frame: At 6 months after recruitment
"CPT3"
To evaluate the benefits of treatment at the neurocognitive level (performance in attention tasks)
Time frame: Baseline
Change in "CPT3"
To evaluate the benefits of treatment at the neurocognitive level (performance in attention tasks)
Time frame: At 3 months after recruitment
Change in "CPT3"
To evaluate the benefits of treatment at the neurocognitive level (performance in attention tasks)
Time frame: At 6 months after recruitment
"BRIEF" survey
To evaluate the benefits of treatment at the neurocognitive level (assessment of executive functions by parents)
Time frame: Baseline
Change in "BRIEF" survey
To evaluate the benefits of treatment at the neurocognitive level (assessment of executive functions by parents)
Time frame: At 3 months after recruitment
Change in "BRIEF" survey
To evaluate the benefits of treatment at the neurocognitive level (assessment of executive functions by parents)
Time frame: At 6 months after recruitment
"BASC" survey
To evaluate the benefits of treatment at the neurocognitive level (Behavior Assesment)
Time frame: Baseline
Change in "BASC" survey
To evaluate the benefits of treatment at the neurocognitive level (Behavior Assesment)
Time frame: At 3 months after recruitment
Change in "BASC" survey
To evaluate the benefits of treatment at the neurocognitive level (Behavior Assesment)
Time frame: At 6 months after recruitment
Statistically significant changes in neuroimaging tests
Changes in structural imaging (white matter volume, gray matter volume and total intracranial volume, brain lobe volume and voxel-based morphometry), in diffusion (diffusion maps and structural connectivity) and in functional imaging (resting-state fMRI and task-based fMRI).
Time frame: At 3 months after recruitment
Statistically significant changes in neuroimaging tests
Changes in structural imaging (white matter volume, gray matter volume and total intracranial volume, brain lobe volume and voxel-based morphometry), in diffusion (diffusion maps and structural connectivity) and in functional imaging (resting-state fMRI and task-based fMRI).
Time frame: At 6 months after recruitment
Immune and inflammatory biomarkers
Study of lymphocyte populations by parametric flow cytometry (T lymphocytes, B lymphocytes, NK lymphocytes, NK T lymphocytes) and inflammatory cytokines by LUMINEX (IL-2, IL-4, IL-6, TNF alpha, IFN gamma, IL-10, IL-17a, IL-1R antagonist)
Time frame: Baseline
Statistically significant changes in immune and inflammatory biomarkers
Study of lymphocyte populations by parametric flow cytometry (T lymphocytes, B lymphocytes, NK lymphocytes, NK T lymphocytes) and inflammatory cytokines by LUMINEX (IL-2, IL-4, IL-6, TNF alpha, IFN gamma, IL-10, IL-17a, IL-1R antagonist)
Time frame: At 3 months after recruitment
Statistically significant changes in immune and inflammatory biomarkers
Study of lymphocyte populations by parametric flow cytometry (T lymphocytes, B lymphocytes, NK lymphocytes, NK T lymphocytes) and inflammatory cytokines by LUMINEX (IL-2, IL-4, IL-6, TNF alpha, IFN gamma, IL-10, IL-17a, IL-1R antagonist)
Time frame: At 6 months after recruitment
Prevalence
To define the prevalence of neurocognitive deficit in cancer survivors in our population.
Time frame: Baseline
Perception of the family measured by satisfaction survey
To analyze the psychological and emotional perception of family members after a controlled intervention using video games.
Time frame: Through study completion, 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.